Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

RNA Interference Therapy Competitive Landscape Research 2026: Comprehensive Insights About 40+ Companies and 90+ Drugs - Collaborations, Acquisitions, and Licensing Deals

globenewswire.com
ALNY Alnylam Pharmaceuticals is featured prominently in the report, with multiple products (Lumasiran, Cemdisiran, ALN-6400) mentioned across different development stages. The company is a key player in the RNA Interference Therapy space. REGN Regeneron Pharmaceuticals is mentioned in collaboration with Alnylam Pharmaceuticals for Cemdisiran, a late-stage product. This indicates involvement in the RNA Interference Therapy sector.

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "RNA Interference Therapy-Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.

The "RNA Interference Therapy - Competitive Landscape 2026" report offers an in-depth analysis of over 40 companies and more than 90 drugs within the RNA Interference Therapy sector. This comprehensive document evaluates therapeutics based on product type, development stage, route of administration, and molecule type, while also highlighting inactive pipeline products worldwide.

RNA interference (RNAi) acts as a crucial mechanism for gene silencing, employing small RNA guides for sequence-specific mRNA degradation. Developed initially from C. elegans, RNAi therapeutics provide promising alternative treatment options, especially where conventional drug technologies such as small-molecule drugs and monoclonal antibodies face challenges. This makes RNAi a potential game-changer in drug development, especially in addressing mutational resistance in infectious diseases.

RNAi therapies utilize small RNA duplexes, including miRNA mimics, siRNAs, shRNAs, and dsiRNAs, each with ongoing clinical trials. Key focus areas of RNAi include managing toxicity, efficacy, and delivery, given that improper target recognition or immunogenic effects can pose risks.

While RNAi technology progresses rapidly, complexities in its mechanism still require research. Nevertheless, its transformative impact on functional genomics and potential in therapeutic interventions is clear, especially for conditions related to viral infections, including studies on SARS-CoV and SARS-CoV-2.

Latest Developments

RNA Interference Therapy: Company and Product Profiles

Companies Featured

Key Topics Covered:

Introduction

Executive Summary

RNA Interference Therapy: Overview

RNA Interference Therapy - Analytical Perspective: In-depth Commercial Assessment

Competitive Landscape

Therapeutic Assessment

RNA Interference Therapy: Company and Product Profiles (Marketed Therapies)

Alnylam Pharmaceuticals

Lumasiran

RNA Interference Therapy: Company and Product Profiles (Pipeline Therapies)

Late Stage Products (Phase III)

Alnylam Pharmaceuticals/Regeneron Pharmaceuticals

Cemdisiran

Mid Stage Products (Phase II)

Alnylam Pharmaceuticals

ALN-6400

Early Stage Products (Phase I)

ADARx Pharmaceuticals

ADX-850

Preclinical and Discovery Stage Products

Avidity Biosciences

AOC 1086

Inactive Products

RNA Interference Therapy- Unmet needs

RNA Interference Therapy - Market drivers and barriers

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/vtaxrm

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.